Florian Lordick, Oncologist, Professor of Medicine at the University of Leipzig, Head of Medical Oncology, Director of the Comprehensive Cancer Center Central Germany, shared a post on LinkedIn about a paper by Alberto Giovanni Leone et al. published in the European Journal of Cancer:
“Congratulations to Alberto Giovanni Leone, Filippo Pietrantonio, and co-authors!
Delighted to see the publication of this important meta-analysis evaluating progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line immunotherapy trials for gastro-esophageal cancers.
This comprehensive investigation – spanning 18 randomized clinical trials – provides crucial evidence for the validity of surrogate endpoints in the era of immune checkpoint inhibition.
The findings show that:
- In gastro-esophageal adenocarcinoma (GEA), particularly among patients with high PD-L1 expression, PFS demonstrates a moderate to strong correlation with OS – supporting its use as a co-primary endpoint in future trials.
- In esophageal squamous cell carcinoma (ESCC), correlations remain weaker, reinforcing the continued importance of OS-based evaluation in this setting.
A special congratulations to Alberto Giovanni Leone for leading this effort and uniting such a dedicated global team of researchers in gastrointestinal immuno-oncology. This collaborative, methodologically rigorous work represents a significant contribution toward more efficient and evidence-based trial design.”
Title: Progression-free survival as a surrogate for overall survival in gastro-esophageal cancer trials with immunotherapy: A meta-analysis
Authors: Alberto Giovanni Leone, Fausto Petrelli, Samuel J. Klempner, Elizabeth C. Smyth, Raghav Sundar, Florian Lordick, Sylvie Lorenzen, Micheal Masetti, Radka Obermannova, Maria Alsina, Yelena Y. Janjigian, Filippo Pietrantonio
You can read the Full Article in the European Journal of Cancer.
More posts featuring Florian Lordick.